Supernus Pharmaceuticals ... (SUPN)
Supernus Pharmaceuticals Statistics
Share Statistics
Supernus Pharmaceuticals has 55.81M shares outstanding. The number of shares has increased by 0.88% in one year.
| Shares Outstanding | 55.81M |
| Shares Change (YoY) | 0.88% |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 53.35M |
| Failed to Deliver (FTD) Shares | 75 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 6.02M, so 10.9% of the outstanding shares have been sold short.
| Short Interest | 6.02M |
| Short % of Shares Out | 10.9% |
| Short % of Float | 11.39% |
| Short Ratio (days to cover) | 15.63 |
Valuation Ratios
The PE ratio is 26.97 and the forward PE ratio is 20.65. Supernus Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 26.97 |
| Forward PE | 20.65 |
| PS Ratio | 3.01 |
| Forward PS | 1.9 |
| PB Ratio | 1.92 |
| P/FCF Ratio | 11.64 |
| PEG Ratio | 0 |
Enterprise Valuation
Supernus Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.54B.
| EV / Earnings | 20.91 |
| EV / Sales | 2.33 |
| EV / EBITDA | 8.66 |
| EV / EBIT | 18.92 |
| EV / FCF | 9.02 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.35 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.2 |
| Cash Flow / Debt | 5.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.07% and return on capital (ROIC) is 5.76%.
| Return on Equity (ROE) | 0.07% |
| Return on Assets (ROA) | 0.05% |
| Return on Capital (ROIC) | 5.76% |
| Revenue Per Employee | $981,924.33 |
| Profits Per Employee | $109,591.99 |
| Employee Count | 674 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.43 |
Taxes
| Income Tax | 24M |
| Effective Tax Rate | 0.25 |
Stock Price Statistics
The stock price has increased by 3.72% in the last 52 weeks. The beta is 0.84, so Supernus Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | 3.72% |
| 50-Day Moving Average | 36.88 |
| 200-Day Moving Average | 33.03 |
| Relative Strength Index (RSI) | 30.97 |
| Average Volume (20 Days) | 450.36K |
Income Statement
In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M and earned 73.86M in profits. Earnings per share was 1.34.
| Revenue | 661.82M |
| Gross Profit | 583.91M |
| Operating Income | 81.67M |
| Net Income | 73.86M |
| EBITDA | 178.28M |
| EBIT | 81.67M |
| Earnings Per Share (EPS) | 1.34 |
Balance Sheet
The company has 69.33M in cash and 34.27M in debt, giving a net cash position of 35.06M.
| Cash & Cash Equivalents | 69.33M |
| Total Debt | 34.27M |
| Net Cash | 35.06M |
| Retained Earnings | 556.43M |
| Total Assets | 1.37B |
| Working Capital | 393.67M |
Cash Flow
In the last 12 months, operating cash flow was 171.95M and capital expenditures -725K, giving a free cash flow of 171.23M.
| Operating Cash Flow | 171.95M |
| Capital Expenditures | -725K |
| Free Cash Flow | 171.23M |
| FCF Per Share | 3.11 |
Margins
Gross margin is 88.23%, with operating and profit margins of 12.34% and 11.16%.
| Gross Margin | 88.23% |
| Operating Margin | 12.34% |
| Pretax Margin | 14.79% |
| Profit Margin | 11.16% |
| EBITDA Margin | 26.94% |
| EBIT Margin | 12.34% |
| FCF Margin | 25.87% |
Dividends & Yields
SUPN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 4.22% |
| FCF Yield | 9.66% |
Analyst Forecast
The average price target for SUPN is $36, which is 13.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $36 |
| Price Target Difference | 13.3% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 4.76 |
| Piotroski F-Score | 5 |